SLC6A3 and Parkinson disease: Given the role of DAT in the regulation of dopamine release and the long-hypothesized connection between altered dopamine neurotransmission and PD, studies of DAT regulation in physiological and pathological conditions remain a promising avenue to identify early biomarkers and therapeutic targets for PD.